Circadian changes in pharmacokinetics of cyclosporin in healthy volunteers.

被引：0
|
作者：
Choi, JS [1 ]
Park, HJ [1 ]
机构：
[1] Chosun Univ, Coll Pharm, Dong Gu, Kwangju 501759, South Korea
来源：
RESEARCH COMMUNICATIONS IN MOLECULAR PATHOLOGY AND PHARMACOLOGY | 1999年 / 103卷 / 01期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Circadian changes in the pharmacokinetics of cyclosporin were evaluated after oral administration of the drug, 300 mg, at 09:00 and 20:00 to twelve healthy male subjects. At 09:00, the blood concentrations of cyclosporin were higher, the area under the blood concentration-time curve from time 0 to time infinity was significantly greater (9.70 versus 8.42 mu g.hr/ml), and the renal clearance was significantly slower (1.14 versus 1.48 ml/min) than those at 22:00. The terminal half-life, peak concentration, and time to reach peak concentration were not significantly different between two groups.
引用
收藏
页码：109 / 112
页数：4
相关论文
共 50 条
  • [31] Pharmacokinetics and tolerability of the combination of lamotrigine (LTG) and oxcarbazepine (OXC) in healthy volunteers.
    Theis, JG
    Sidhu, J
    Job, S
    Palmer, JE
    Ratcliffe, JM
    Ascher, JA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P22 - P22
  • [32] Pharmacokinetics of high doses of cyanocobalamin administered by IV injection in healthy volunteers.
    Nava-Ocampo, AA
    Koren, G
    Pastrak, A
    Cruz, T
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P84 - P84
  • [33] Pharmacokinetics (PK) and pharmacodynamics (PD) of interferon β-1a in healthy volunteers.
    Buchwalder, PA
    Buclin, T
    Trinchard, I
    Munafo, A
    Biollaz, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 166 - 166
  • [34] Effects of erythromycin or rifampin on steady state losartan pharmacokinetics in healthy volunteers.
    Williamson, KM
    Patterson, JH
    Pieper, JA
    McQueen, RH
    Adams, KF
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (02) : PII31 - PII31
  • [35] Concomitant pharmacokinetics (PK) of micafungin, an echinocandin antifungal, and tacrolimus in healthy volunteers.
    Townsend, R
    Hebert, M
    Wisemandle, W
    Bekersky, I
    JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (09): : 1055 - 1055
  • [36] EFFECT OF AGE ON THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF INTRAVENOUS RIVIPANSEL IN HEALTHY VOLUNTEERS.
    Tammara, B.
    Ryan, K.
    Plotka, A.
    Shafer, F.
    Wei, H.
    Readett, D.
    Fang, A.
    Korth-bradley, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S89 - S89
  • [37] MIDAZOLAM PHARMACOKINETICS ARE NOT INFLUENCED BY POLYMORPHISMS OF HEPATIC OATP IBI IN HEALTHY VOLUNTEERS.
    Ziesenitz, V. C.
    Koenig, S. K.
    Weiss, J.
    Burhenne, J.
    Haefeli, W. E.
    Mikus, G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S61 - S61
  • [38] Pharmacokinetics of PD 0200390 following multiple dose administration to healthy volunteers.
    Corrigan, B. W.
    Werth, J.
    Moton, A.
    Alvey, C.
    Feltner, D.
    Ouellet, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S30 - S30
  • [39] POPULATION PHARMACOKINETICS OF ORAL CEPHALOSPORINS IN CYSTIC FIBROSIS PATIENTS AND HEALTHY VOLUNTEERS.
    Sutaria, D.
    Jiao, Y.
    Tao, X.
    Stephan, U.
    Kinzig, M.
    Bulitta, J.
    Sorgel, F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S112 - S112
  • [40] Pharmacokinetics and safety of mirtazapine in Caucasian and Japanese young healthy male volunteers.
    Peeters, P
    Brett, M
    van Heuvel, M
    Sitsen, A
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P36 - P36
12345